Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) presented new Phase 2 data showing statistically significant reductions in lesion bleeding among patients treated with QTORIN rapamycin for cutaneous venous malformations, …
Palvella Advances Rare Disease Program With Phase 2 Data Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) recently dosed the first patients in a Phase 2 study evaluating QTORIN rapamycin gel for angiokeratomas, a rare vascular-related skin disorder with no …
Palvella Doses First Patients in Rare Disease Skin Trial Read More
WAYNE, PA — A peer-reviewed study of Cagent Vascular’s Serranator catheter reported high procedural success and wound-healing rates in patients with chronic limb-threatening ischemia, findings that arrive as new reimbursement …
Cagent Study Shows Strong Outcomes in High-Risk Limb Cases Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) recently published results from a Phase 2/3 clinical trial evaluating its investigational drug buntanetap in patients with mild to moderate Alzheimer’s disease, …
Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported full results from a Phase 1a clinical trial of its ATI-052 antibody and outlined plans to advance multiple programs, including selecting …
Aclaris Reports Phase 1a Results for ATI-052, Advances Pipeline Read More
WASHINGTON, D.C. — Federal regulators are moving to speed up drug development by launching real-time clinical trials that allow safety data and results to be reviewed as studies are underway …
FDA Pushes Faster Drug Approvals With Real-Time Trials Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will present clinical results from its QTORIN™ rapamycin program at the ISSVA World Congress 2026 in Philadelphia, with data from Phase 3 …
Palvella to Present QTORIN Study Data at ISSVA 2026 Conference Read More
HARRISBURG, PA — Pennsylvania researchers can now apply for $5 million in state funding aimed at advancing treatments and potential cures for neurodegenerative diseases affecting hundreds of thousands of residents.
PA Opens $5M Grant Push to Fight Alzheimer’s, ALS, Parkinson’s Read More
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has completed enrollment and dosing in its Phase 2/3 clinical trial evaluating a gene therapy candidate for Stargardt disease.
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced the publication of an article detailing the development of its lead drug candidate buntanetap as the company continues clinical trials for …
Annovis Bio Highlights Buntanetap Development in Published Article Read More